ring finger and CCCH-type domains 2Genealiases: MNAB · RNF164
Q-omics provides the consensus-scored RC3H2 profile across patient tissues and cancer cell-line models. RC3H2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RC3H2 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, RC3H2 RNA expression shows 21,315 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where RC3H2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RC3H2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RC3H2 survival associations across molecular data types. RC3H2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RC3H2 RNA expression–survival associations across cancer types. High RC3H2 expression shows unfavorable associations in ACC, HNSC, BLCA and MESO, but favorable associations in KIRC and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RC3H2 RNA expression.
This table summarizes RC3H2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RC3H2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RC3H2 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, CHOL and STAD. The HNSC box plot shows higher RC3H2 RNA expression in tumor versus normal tissue (log2 FC = +1.188, t-test p < 0.001).
This table shows molecular features associated with RC3H2 in patient tissues and cancer cell lines. In patient samples, RC3H2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RC3H2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
